Competitive androgen receptor antagonists are used to treat prostate cancer but, even in the presence of such drugs, overexpression of androgen receptors can drive cellular proliferation ...

But of course, the last few years, really the last decade to decade and a half, has been the advent of what we call, now call ARPIs, or androgen receptor pathway inhibitors. And these are really ...

Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...